News

This collaboration will combine the Mekonos novel ex vivo delivery platform with bit.bio’s opti-ox precision cellular reprogrammin...

Statement from our CFO on the situation concerning SVB.

bit.bio will use Automata to automate a key aspect of its production of iPSC derived human cells

Further products in CNS portfolio aim to address the translation gap and accelerate research and drug discovery for neurodegenerat...

New advisors will provide important and independent guidance.

Products aim to address the translation gap and accelerate research and drug discovery for neurodegenerative disease.

The award was presented at evening ceremony in central London.

The posters demonstrate the capability of opti-ox technology to create any human cell.